ASX Announcements
Notification of cessation of securities - CSL
Appendix 3H (Notification of cessation of securities)
- Sep 6, 2024
- 4 pages
Notification of cessation of securities - CSL
Appendix 3H (Notification of cessation of securities)
- Sep 6, 2024
- 4 pages
Application for quotation of securities - CSL
Appendix 2A (Application for Quotation of Securities)
- Sep 2, 2024
- 6 pages
This Month
- Opinion
- Investing
How Australia’s ‘magnificent 10’ contributed to returns over 20 years
How costly was failing to pick the ASX’s 10 top performers over the past two decades? Vanguard did the sums
- Carole Okigbo
August
- Updated
- Earnings season
CSL’s bullish earnings call dimmed by stumbles at new Vifor business
The country’s largest pharmaceutical company says it expects double-digit earnings growth for the next five years as its core blood products business surges.
- Updated
- Michael Smith
- Opinion
- Chanticleer
‘I want to win every time’: The Olympic-style goal driving CSL’s boss
The company’s growth forecasts for next year are a touch weaker than the market expected. But inspired by the Games, CEO Paul McKenzie is focused on another goal.
- Updated
- James Thomson
- Results Wrap
- Chanticleer
How Temple & Webster won day two of profit season
CSL was the headline result, but it was Seek which was hit hardest on results day. Here’s what caught our eye.
- James Thomson and Anthony Macdonald
US eyes Iran attack; Musk interviews Trump; Airtrunk’s $20b tax test
Read everything that’s happened in the news so far today.
July
CSL wins global avian flu vaccine contracts
Australian pharmaceutical giant CSL is to supply up to 45 million shots of its avian flu vaccine to Europe and the US as health authorities prepare for possible human infection from the dangerous H5 strain.
- Tom Burton
- Opinion
- Investing
How to invest in the golden age of health disruption
Investing in healthcare in today’s market combines exposure to two key drivers – structural demand growth and disruptive innovation.
- Andrew McAuley
June
Woolworths, CSL among ASX giants that should sell foreign assets
A wave of Australian companies are ditching their overseas businesses to bring capital back to Australia. MST Marquee says there are more that should do the same.
- Alex Gluyas
A biotech boom for the ASX? This fundie thinks so
SG Hiscock’s Rory Hunter thinks CSL could “absolutely” hit $500, says biotechs are ripe for M&A, and reveals a hidden gem flying under the market’s radar.
- Alex Gluyas
- Exclusive
- Funding
Super funds, CSL pour $270m into venture capital fund
Australia’s largest life science investment fund, Brandon Capital, has banked $270 million of a planned $350 million raise for its sixth VC fund.
- Updated
- Tess Bennett
May
Biotech start-up raising $20m pre-IPO amid missed payment claims
Plasma start-up Aegros has been accused of not paying suppliers and missing payroll, put is still planning on a 2025 IPO.
- Yolanda Redrup and Carrie LaFrenz
April
This fundie says CSL is a $500 stock
ECP Asset Management’s Sam Byrnes expects the blood plasma collector’s return on capital to substantially improve and remains bullish on IDP Education even though its share price has tumbled this year.
- Joanne Tran
The eight stocks most loved by Australia’s best fund managers
Despite the headwinds, CSL is still loved by the top stock pickers. CBA and BHP are also widely held – but not as widely as expected.
- Joshua Peach
Macquarie tips CSL shares to hit $500
Some of the biotechnology giant’s shareholders are sceptical about the investment bank’s call, which is detailed to clients in a 55-page note.
- Updated
- Alex Gluyas
March
Blood giant CSL works up $US1 billion-plus bond deal; banks mandated
CSL has a host of top-tier investment banks working on the deal, namely Bank of America, Citi, JPMorgan and HSBC.
- Sarah Thompson, Kanika Sood and Emma Rapaport
Dick Humphry, inventor of shareholder democracy, dies at 85
A man whose habits and approach were set in the “old school”, Richard Humphry nevertheless led a technology-driven revolution in Australia’s financial markets.
- Andrew Clark
February
Why we can’t agree on WFH | Where mortgage stress is rising | What to drink mid-air
Read everything that’s happened in the news so far today.
The juggernaut keeping CSL’s valuation pumping despite Ozempic threat
CSL managed to shrug off the Ozempic effect and this week’s setback linked to a disappointing phase three trial thanks to its CSL Behring blood products business.
- Updated
- Ben Potter
- Opinion
- Chanticleer
What we learnt from CSL, Challenger, Seek and Breville’s results
Investors in CSL and Breville have growth questions on their mind, while Seek’s downgrade sent shares skidding. Meanwhile, at Challenger, a bro-mance is brewing.
- James Thomson and Anthony Macdonald
Macquarie’s top earner departs | ATO staff in GST fraud | ANZ to cut 170 jobs
Read everything that’s happened in the news so far today.